Unknown

Dataset Information

0

Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition.


ABSTRACT: To identify therapeutic targets for KRAS mutant pancreatic cancer, we conduct a druggable genome small interfering RNA (siRNA) screen and determine that suppression of BCAR1 sensitizes pancreatic cancer cells to ERK inhibition. Integrative analysis of genome-scale CRISPR-Cas9 screens also identify BCAR1 as a top synthetic lethal interactor with mutant KRAS. BCAR1 encodes the SRC substrate p130Cas. We determine that SRC-inhibitor-mediated suppression of p130Cas phosphorylation impairs MYC transcription through a DOCK1-RAC1-β-catenin-dependent mechanism. Additionally, genetic suppression of TUBB3, encoding the βIII-tubulin subunit of microtubules, or pharmacological inhibition of microtubule function decreases levels of MYC protein in a calpain-dependent manner and potently sensitizes pancreatic cancer cells to ERK inhibition. Accordingly, the combination of a dual SRC/tubulin inhibitor with an ERK inhibitor cooperates to reduce MYC protein and synergistically suppress the growth of KRAS mutant pancreatic cancer. Thus, we demonstrate that mechanistically diverse combinations with ERK inhibition suppress MYC to impair pancreatic cancer proliferation.

SUBMITTER: Waters AM 

PROVIDER: S-EPMC8340308 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition.

Waters Andrew M AM   Khatib Tala O TO   Papke Bjoern B   Goodwin Craig M CM   Hobbs G Aaron GA   Diehl J Nathaniel JN   Yang Runying R   Edwards A Cole AC   Walsh Katherine H KH   Sulahian Rita R   McFarland James M JM   Kapner Kevin S KS   Gilbert Thomas S K TSK   Stalnecker Clint A CA   Javaid Sehrish S   Barkovskaya Anna A   Grover Kajal R KR   Hibshman Priya S PS   Blake Devon R DR   Schaefer Antje A   Nowak Katherine M KM   Klomp Jennifer E JE   Hayes Tikvah K TK   Kassner Michelle M   Tang Nanyun N   Tanaseichuk Olga O   Chen Kaisheng K   Zhou Yingyao Y   Kalkat Manpreet M   Herring Laura E LE   Graves Lee M LM   Penn Linda Z LZ   Yin Hongwei H HH   Aguirre Andrew J AJ   Hahn William C WC   Cox Adrienne D AD   Der Channing J CJ  

Cell reports 20210601 13


To identify therapeutic targets for KRAS mutant pancreatic cancer, we conduct a druggable genome small interfering RNA (siRNA) screen and determine that suppression of BCAR1 sensitizes pancreatic cancer cells to ERK inhibition. Integrative analysis of genome-scale CRISPR-Cas9 screens also identify BCAR1 as a top synthetic lethal interactor with mutant KRAS. BCAR1 encodes the SRC substrate p130Cas. We determine that SRC-inhibitor-mediated suppression of p130Cas phosphorylation impairs MYC transcr  ...[more]

Similar Datasets

| S-EPMC5161652 | biostudies-literature
| S-EPMC5814157 | biostudies-literature
| S-EPMC8338909 | biostudies-literature
| S-EPMC7596241 | biostudies-literature
| S-EPMC4747197 | biostudies-literature
| S-EPMC6534361 | biostudies-literature
| S-EPMC4514964 | biostudies-literature
| S-EPMC11599858 | biostudies-literature
| S-EPMC11898827 | biostudies-literature